Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Amyotrophic Lateral Sclerosis
Interventions: AMT-162; Drug
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 11
States / cities: Phoenix, Arizona • Irvine, California • San Francisco, California + 8 more

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: Evinacumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: Wilmington, Delaware • Boca Raton, Florida • Kansas City, Kansas + 3 more

Conditions: Cancer, Solid Tumor
Interventions: Fludarabine, Cyclophosphamide, IMA101 product, Recombinant human interleukin-2, IMADetect, Atezolizumab; Drug · Biological · Diagnostic Test
Lead sponsor: Immatics US, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers, Elevated CRP
Interventions: MRT-8102, Placebo; Drug
Lead sponsor: Monte Rosa Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Miami, Florida • Lenexa, Kansas • Springfield, Missouri + 1 more

Conditions: Cancer Risk Syndrome
Interventions: AYA-RISE Adolescents and Young Adults Risk Information and Screening Education, Standard clinical visit for genetic counseling; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 12 Years to 24 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 1 more

Conditions: Microbiota, Gut Microbiome, Eczema, Microbiome
Interventions: Tailored Recommendations, Consult Call, Educational Email Series; Dietary Supplement · Behavioral
Lead sponsor: Seeding Inc; Industry
Eligibility: 0 Months to 3 Months
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Rett Syndrome
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 3 Years to 18 Years · Female only
Enrollment: 146 participants
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy
Interventions: ExPEC4V (4 : 4 : 4 : 4), ExPEC4V (4 : 4 : 4 : 8), ExPEC4V (8 : 8 : 8 : 8), ExPEC4V (8 : 8 : 8 : 16), ExPEC4V (16 : 16 : 16 : 16), Placebo; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 848 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 17
States / cities: Mesa, Arizona • Hollywood, Florida • Leesburg, Florida + 14 more

Conditions: Vascular Inflammation, ASCVD, ASCVD Management
Interventions: CANAKINUMAB (ILARIS®), Saline (NaCl 0,9 %) (placebo); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy, Hepatic Impairment
Interventions: T-817MA; Drug
Lead sponsor: FUJIFILM Toyama Chemical Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Healthy Volunteers
Interventions: CG100649 (2 mg), Celecoxib, Placebo capsules, Naproxen, Acetazolamide, CG100649 (8 mg); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cytopenia
Interventions: Emapalumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions: Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device; Combination Product
Lead sponsor: Bellerophon Pulse Technologies; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 43
States / cities: Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 35 more

Conditions: Traumatic Brain Injury
Interventions: Personalized Augmented Cognitive Training (PACT), Enhanced Treatment As Usual; Behavioral
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 18 Years to 55 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: San Diego, California

Conditions: HIV Infections
Interventions: pGA2/JS7 DNA vaccine, Placebo, MVA/HIV62 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 299 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more

Conditions: Salt; Excess, Blood Pressure Disorders
Interventions: Allopurinol, Dietary Intervention; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 22 Years to 33 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hepatitis C
Interventions: BZF961, Ritonavir, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: San Diego, California • Orlando, Florida • San Antonio, Texas

Conditions: Suicide, Suicide, Attempted, Suicide and Self-harm, Suicide Threat
Interventions: Safe Alternatives for Teens and Youth - Parent (SAFETY-P), Treatment As Usual (TAU); Behavioral
Lead sponsor: Jennifer Hughes; Other
Eligibility: 10 Years to 18 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Schizophrenia
Interventions: LB-102; Drug
Lead sponsor: LB Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Oral Cavity Squamous Cell Carcinoma
Interventions: Chemotherapy, Lattice Radiotherapy (LRT); Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: DMG, DIPG
Interventions: TAA-T Cell, BBB Disruption; Biological · Device
Lead sponsor: Children's National Research Institute; Other
Eligibility: 3 Years to 25 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Cancer, Breast Tumor, Cancer of Breast, Cancer of the Breast, Malignant Tumor of Breast, Tumors, Breast
Interventions: BC1 cell line, Bria-OTS regimen and CPI (tislelizumab), Bria-OTS regimen and CPI (tislelizumab) expansion cohort; Biological
Lead sponsor: BriaCell Therapeutics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Healthy Participants
Interventions: Lu AH69593, Itraconazole, Carbamazepine, Midazolam; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK2838232, Cobicistat; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 8 more

Search by objective public record fields.

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

ACTolog in Patients With Solid Cancers

A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP

Intervention For Adolescents and Young Adults (AYAs) With Cancer Risk Syndromes

Flourish: Exploring the Early Infant Gut Microbiome

Development of a Behavioral Outcome Measure for Rett Syndrome (RettBe)

A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

PK Study of T-817 in Subjects With Hepatic Impairment

Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia

Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans with a History of TBI

Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

Uric Acid, Klotho and Salt Sensitivity in Young Adults Born Preterm

Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients

SAFETY-Parent: Online Learning Module to Support Parents of Suicidal Youth

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma

Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

A Trial of Lu AH69593 in Healthy Participants

Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults